Investors focused on the Medical space have likely heard of Genesis Healthcare (GEN), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Genesis Healthcare is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. GEN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GEN's full-year earnings has moved 37.42% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, GEN has returned 11.02% so far this year. Meanwhile, the Medical sector has returned an average of -1.65% on a year-to-date basis. This means that Genesis Healthcare is outperforming the sector as a whole this year.
Looking more specifically, GEN belongs to the Medical - Nursing Homes industry, a group that includes 5 individual stocks and currently sits at #11 in the Zacks Industry Rank. On average, stocks in this group have gained 10.95% this year, meaning that GEN is performing better in terms of year-to-date returns.
GEN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Genesis Healthcare, Inc. (GEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.